Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.680
-0.040 (-1.47%)
At close: Apr 25, 2025, 4:00 PM
2.640
-0.040 (-1.49%)
After-hours: Apr 25, 2025, 7:18 PM EDT
Company Description
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc.
Country | United States |
Founded | 2018 |
IPO Date | Jun 30, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 30 |
CEO | Timothy Noyes |
Contact Details
Address: 930 Winter Street, Suite M-500 Waltham, Massachusetts 02451 United States | |
Phone | 617 443 2400 |
Website | aerovatetx.com |
Stock Details
Ticker Symbol | AVTE |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $14.00 |
CIK Code | 0001798749 |
CUSIP Number | 008064107 |
ISIN Number | US0080641071 |
Employer ID | 83-1377888 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Timothy P. Noyes M.B.A. | Chief Executive Officer and Director |
George A. Eldridge | Chief Financial Officer and Treasurer |
Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer and Secretary |
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer |
Hunter Gillies M.D. | Chief Medical Officer |
Donna Dea | Head of Regulatory Affairs |
Susan Fischer | Executive Vice President of Development Operations |
Stephen K. Yu | Senior Vice President of Quality |
Dr. Sanjeev Khindri | Executive Vice President of Clinical Development |
Dr. Cheryl Lassen BSc., M.D., MBBCh | Senior Vice President of Clinical Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 23, 2025 | 8-K | Current Report |
Apr 21, 2025 | 8-K | Current Report |
Apr 9, 2025 | 425 | Filing |
Apr 9, 2025 | 425 | Filing |
Apr 9, 2025 | 8-K | Current Report |
Apr 9, 2025 | 425 | Filing |
Apr 9, 2025 | 8-K | Current Report |
Apr 7, 2025 | 425 | Filing |
Apr 7, 2025 | 425 | Filing |
Apr 7, 2025 | 8-K | Current Report |